(Q37625441)

21 August 2017

1 reference

title

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. (English)

1 reference

21 August 2017

3

Ranjana Advani

1 reference

21 August 2017

Yok-Lam Kwong

1

1 reference

21 August 2017

Benjamin O Anderson

2

1 reference

21 August 2017

Won-Seog Kim

4

1 reference

21 August 2017

Alexandra M Levine

5

1 reference

21 August 2017

Soon-Thye Lim

6

1 reference

21 August 2017

Asian Oncology Summit

7

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Lancet Oncology Commission

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1093-1101

1 reference

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Development of human lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Natural killer-cell malignancies: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

FDG-PET in T-cell and NK-cell neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Non-nasal natural killer cell lymphoma: not non-nasal after all

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

CD56+ NK lymphomas: clinicopathological features and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970265-7

7 January 2021

10.1016/S1470-2045(09)70265-7

Identifiers

DOI

1 reference

21 August 2017

1 reference